Peer-reviewed veterinary case report
Prolactin levels linked to tumor relapse in female dogs with mammary
By Queiroga, F L et al.·Published in The Veterinary record·2014·Department of Veterinary Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical and prognostic implications of serum and tissue prolactin levels in canine mammary tumours.
- Species:
- dog
Plain-English summary
A group of 39 female dogs with mammary tumors had their prolactin levels tested to see if it could help predict how serious their condition was. The results showed that dogs with malignant tumors had higher prolactin levels, especially those with inflammatory mammary carcinomas, which were linked to a greater chance of the cancer coming back or spreading. This suggests that measuring prolactin could help veterinarians better understand the severity of the cancer and tailor treatments for these dogs.
People also search for: dog mammary tumor treatment · high prolactin levels in dogs · inflammatory mammary carcinoma in dogs
Abstract
The biological implications of serum and tissue prolactin levels in canine mammary tumours (CMT) have been previously described although the influence of this hormone on inflammatory mammary carcinomas as well as its value as prognostic indicator remains to be properly clarified. Prolactin determinations were carried out by enzyme immunoassay in tumour tissue and serum of 39 female dogs with spontaneous CMT and in normal mammary gland and serum of 10 controls. Prolactin levels were higher in the case of CMT compared to controls (P<0.05). In malignant CMT, higher levels of tissue prolactin were associated with the occurrence of tumour relapse and/or distant metastasis (P<0.05). Inflammatory mammary carcinomas presented the highest values for tissue prolactin concentrations with concentrations significantly higher than other malignant non-inflammatory mammary carcinoma tumours (P<0.05). The high levels of prolactin found in cases with poor clinical prognoses, including inflammatory mammary carcinoma, open the possibility of being able to better stratify clinical cases in malignant CMT with a view to tailoring treatment appropriately.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25096592/